Adding Pharmacists to Core Hemophilia Care Teams Improves Outcomes, Patient Costs

September 30th 2022, 11:30pm


A recent study suggests that including a pharmacist in the hemophilia comprehensive care model may improve bleeding outcomes and medication access and adherence, and lead to cost savings.

Managing Bleeding Disorders in Pregnancy Requires Early Diagnosis, Multidisciplinary Care

September 27th 2022, 12:58pm


A recent review details strategies for mitigating the risks faced by pregnant patients with hemophilia or von Willebrand disease and their children.

Review Highlights Potential of Emicizumab Prophylaxis in Acquired Hemophilia A

September 22nd 2022, 3:30pm


Morbidity and mortality remain high for patients with acquired hemophilia A, and advances in immunotherapy and hemostatic therapy are needed to improve outcomes.

Surgeries Can Be Safe, Effective in Patients With Hemophilia A on Emicizumab Prophylaxis

September 17th 2022, 9:10pm


The study pooled data from 4 clinical trials to gain insight into surgical outcomes in this complex population.

ICER Releases Draft Evidence Report on Gene Therapies for Hemophilia A and B

September 17th 2022, 4:51pm


Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.

Review Looks at Impact of SDOH on Bleeding Disorders

September 9th 2022, 8:20pm


More than 3 million Americans have inherited bleeding disorders, and social determinants of health (SDOH) play a role in a number of ways, including cost for treatment, difficulty accessing specialists, educational barriers, and more.

Case Study Chronicles Onset and Treatment of Acquired Hemophilia A Following HSCT for ALL

September 6th 2022, 4:16pm


The case emphasizes the importance for clinician awareness of the potential for rare immune-mediated disorders, including acquired hemophilia A (AHA), following allogeneic hematopoietic stem cell transplantation (HSCT).

Systematic Approaches to Patient Educational Needs May Benefit Those With Bleeding Disorders

September 2nd 2022, 4:30pm


Nurse-led education is an essential aspect of care for patients with bleeding disorders, but there is currently a lack of research on specific strategies to improve patient self-management through education.

Walgreens’ Ray Tancredi Weighs in on Expensive Hemophilia Gene Therapies in the Pipeline

May 13th 2022, 5:59pm


Gene therapies in the pipeline to treat hemophilia will be very expensive, but they also seem to be very efficacious, and multiple could hit the market between now and 2024, said Ray Tancredi, RPh, MBA, CSP, divisional vice president, specialty pharmacy development and brand Rx/vaccine purchasing, Walgreens.

Hemophilia A Gene Therapy Reduced Bleeding Events, Need for Clotting Factors

March 16th 2022, 9:00pm


The phase 3 trial of valoctocogene roxaparvovec for severe hemophilia A showed it reduced bleeding events as well as the use of factor VIII concentrates.